Limits...
The diagnostic performance of serum MUC5AC for cholangiocarcinoma

View Article: PubMed Central - PubMed

ABSTRACT

Specific diagnostic biomarker for cholangiocarcinoma (CCA) has been lacking. This systematic review and meta-analysis was performed aiming to investigate serum MUC5AC's diagnostic performance on CCA.

Studies investigating serum MUC5AC's diagnostic value on CCA were retrieved from Pubmed, Embase, and Cochrane Library. The methodology quality of included studies was assessed according to QUADAS-2. Diagnostic 2 × 2 table was extracted from each eligible study, Meta-disc 1.4 was used for statistical analysis, data synthesis was done using a random-effects model. Subgroup analyses were conducted according to region and array method.

Six eligible studies were identified, a total of 1213 patients were involved in the meta-analysis. The AUC on SROC was 0.9138, and the Q∗ was 8463. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio (DOR) were 0.69 (95% CI: 0.65–0.73), 0.93 (95% CI: 0.91–0.95), 8.99 (95% CI: 5.65–14.30), 0.33 (95% CI: 0.24–0.46), and 33.98 (95% CI: 20.12–57.40), respectively. Targeting MUC5AC's epitope has a higher pooled sensitivity than targeting MUC5AC protein (0.77 vs 0.63). There was substantial cross-study heterogeneity.

Serum MUC5AC might be potentially used as a surrogate marker in the diagnosis of CCA. However, the appropriate array method and the optimum cut-off value are yet to be decided.

No MeSH data available.


Flow chart illustrating literature search and screening.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998430&req=5

Figure 1: Flow chart illustrating literature search and screening.

Mentions: A total of 103 articles were initially extracted, 32 records remained after duplicates were removed. Later, 11 full-text articles were potentially eligible for the meta-analysis; however, 2 of those studies that used IHC method and 2 articles that investigated serum MUC5AC's diagnostic value on other diseases were thus excluded. Seven studies met the inclusion criteria; however, among 5 studies from Thailand, 2 were excluded after screening for patients’ overlapping,[8,9] so 6 studies were finally included[8,10–14] (Fig. 1).


The diagnostic performance of serum MUC5AC for cholangiocarcinoma
Flow chart illustrating literature search and screening.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998430&req=5

Figure 1: Flow chart illustrating literature search and screening.
Mentions: A total of 103 articles were initially extracted, 32 records remained after duplicates were removed. Later, 11 full-text articles were potentially eligible for the meta-analysis; however, 2 of those studies that used IHC method and 2 articles that investigated serum MUC5AC's diagnostic value on other diseases were thus excluded. Seven studies met the inclusion criteria; however, among 5 studies from Thailand, 2 were excluded after screening for patients’ overlapping,[8,9] so 6 studies were finally included[8,10–14] (Fig. 1).

View Article: PubMed Central - PubMed

ABSTRACT

Specific diagnostic biomarker for cholangiocarcinoma (CCA) has been lacking. This systematic review and meta-analysis was performed aiming to investigate serum MUC5AC's diagnostic performance on CCA.

Studies investigating serum MUC5AC's diagnostic value on CCA were retrieved from Pubmed, Embase, and Cochrane Library. The methodology quality of included studies was assessed according to QUADAS-2. Diagnostic 2 × 2 table was extracted from each eligible study, Meta-disc 1.4 was used for statistical analysis, data synthesis was done using a random-effects model. Subgroup analyses were conducted according to region and array method.

Six eligible studies were identified, a total of 1213 patients were involved in the meta-analysis. The AUC on SROC was 0.9138, and the Q∗ was 8463. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio (DOR) were 0.69 (95% CI: 0.65–0.73), 0.93 (95% CI: 0.91–0.95), 8.99 (95% CI: 5.65–14.30), 0.33 (95% CI: 0.24–0.46), and 33.98 (95% CI: 20.12–57.40), respectively. Targeting MUC5AC's epitope has a higher pooled sensitivity than targeting MUC5AC protein (0.77 vs 0.63). There was substantial cross-study heterogeneity.

Serum MUC5AC might be potentially used as a surrogate marker in the diagnosis of CCA. However, the appropriate array method and the optimum cut-off value are yet to be decided.

No MeSH data available.